Maternal Serum Screening for Downs Syndrome, Open Neural Tube Defects and Trisomy 18

Abstract Maternal serum screening identifies women at an increased risk of a pregnancy with Down's syndrome or trisomy 18 or an open neural tube defect. The triple test, consisting of maternal serum α-fetoprotein, unconjugated estriol and human chorionic gonadotropin was carried out by a chemiluminescence immunoassay method in our laboratory. The study consisted of 373 pregnant women. The gestational range for the study group was 14–22 weeks. The mean maternal age for the study group was 28.53 ± 5.46 years (range 17.4 to 43.5 years); 9.1% of the women were considered at high risk for Down's syndrome based on the test results. In our study the detection rate for Down's syndrome by prenatal karyotyping was 66.6%. Maternal serum screening allows reduction of the number of women requiring amniocentesis without a significant decrease in the detection rate.

[1]  F. Malone,et al.  First-trimester screening for aneuploidy: research or standard of care? , 2000, American journal of obstetrics and gynecology.

[2]  L. Boots,et al.  Prospective evaluation of free beta-subunit of human chorionic gonadotropin and dimeric inhibin A for aneuploidy detection. , 1999, American journal of obstetrics and gynecology.

[3]  H. Cuckle,et al.  Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency , 1999, Prenatal diagnosis.

[4]  R. Bahado-Singh,et al.  New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age. , 1998, American journal of obstetrics and gynecology.

[5]  C. Ananth,et al.  An economic evaluation of prenatal strategies for detection of trisomy 18. , 1998, American journal of obstetrics and gynecology.

[6]  L. Boots,et al.  Alpha‐fetoprotein, free beta‐human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three‐analyte, multiple‐marker screening test for fetal Down syndrome , 1998, American Journal of Obstetrics and Gynecology.

[7]  R. Williamson,et al.  Prospective evaluation of prenatal maternal serum screening for trisomy 18. , 1998, American journal of obstetrics and gynecology.

[8]  K. Wenstrom,et al.  α-Fetoprotein, free β-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome , 1997 .

[9]  A. Hackshaw,et al.  Detection of Pregnancies with Trisomy 18 in Screening Programmes for Down's Syndrome , 1995, Journal of medical screening.

[10]  L. Boots,et al.  Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old. , 1995, American journal of obstetrics and gynecology.

[11]  J. Canick,et al.  Risk‐based prenatal screening for trisomy 18 using alpha‐fetoprotein, unconjugated oestriol and human chorionic gonadotropin , 1995, Prenatal diagnosis.

[12]  J. Canick,et al.  Prenatal screening for Down's syndrome with use of maternal serum markers. , 1992, The New England journal of medicine.

[13]  S. Yagel,et al.  The role of midtrimester targeted fetal organ screening combined with the "triple test" and maternal age in the diagnosis of trisomy 21: a retrospective study. , 1998, American journal of obstetrics and gynecology.

[14]  C. Burtis Tietz textbook of Clinical Chemistry , 1994 .